If you carry a standalone Medicare drug plan, the only question that really matters each fall is whether your premium is about to move and by how much. The answer for 2027 begins with a figure that never appears on a bill: a national benchmark Medicare uses to split the cost of the drug program between the government and the people enrolled in it. That benchmark has now been set, and the temporary program that had been cushioning standalone drug plans against exactly this kind of swing is being retired at the same time.
CMS is ending the Part D Premium Stabilization Demonstration after 2026
On July 28, 2026, the Centers for Medicare & Medicaid Services released preliminary technical bid information for Medicare Part D contract year 2027 and used the same release to close the book on a program it had been running since 2025. In its own language, the agency “is announcing the conclusion of the Part D Premium Stabilization Demonstration, a voluntary demonstration for standalone prescription drug plans implemented in CY 2025 to address volatility and variation in standalone premiums following benefit changes mandated by the Inflation Reduction Act (IRA).”
The stated reason is that plans no longer need the cushion. CMS wrote that “for CY 2027, CMS bid analysis indicates that Part D plan sponsors had sufficient experience under the redesigned Part D benefit to support their assumptions in developing the prescription drug plan bids. Therefore, CMS will discontinue the demonstration at the end of CY 2026 to return the program to operating under traditional market conditions in CY 2027.” That is a decision already taken, not a proposal out for comment. The demonstration was voluntary, it ran for two plan years, and 2027 is the first year priced without it.
For a household, “traditional market conditions” is not an abstraction. It means the prices standalone drug plans quote for 2027 were built without a federal program designed to hold their year-over-year swings in check.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
The Inflation Reduction Act’s 6 percent cap produced a $41.33 base beneficiary premium
The base beneficiary premium, or BBP, is the national anchor Medicare recalculates every year. For 2027 it is $41.33, up from $38.99 in 2026. The $2.34 increase is not an accident of the market. It is precisely what the statute allows, because the Inflation Reduction Act limits annual growth in the base beneficiary premium to 6 percent a year for 2024 through 2029.
The formula takes whichever of two calculations comes out lower: the prior year’s premium raised by 6 percent, or the beneficiary premium percentage applied to the national average monthly bid amount. CMS actuaries showed the arithmetic: “The result of calculation A is $41.33. 2026 BBP x 1.06 or $38.99 x 1.06 = $41.33. The result of calculation B is $94.06. Therefore, the Part D BBP for CY 2027 is $41.33.”
Sit with that second result for a moment. Without the cap, the formula would have landed on $94.06, more than twice the figure that will actually be used. The cap runs only through 2029, which makes the distance between those two calculations the most consequential thing in the entire release.
The base beneficiary premium is not the premium you will pay
This is the part that gets mangled every year, so it is worth being blunt: nobody is being told they will pay $41.33 a month for drug coverage in 2027. CMS says as much itself, in a footnote to the same release, noting that “the actual Part D premiums paid by individual beneficiaries equal the BBP adjusted by several factors. In practice, premiums vary significantly from one Part D plan to another and seldom equal the base beneficiary premium.” The agency describes the figure as “the starting point for calculating a plan-specific basic Part D premium.”
Five things move your number off that starting point. The difference between your plan’s standardized bid and the national average bid pushes it up or down. A supplemental premium adds to it. A late enrollment penalty increases it. A Medicare Advantage plan with drug coverage can apply rebates to buy the Part D premium down. And the low-income premium subsidy can reduce or eliminate it outright. Medicare’s own plain-English page on drug coverage makes the same point without the arithmetic: each plan varies in cost, and your total depends on which one you join.
What the $296.05 national average bid does behind the scenes
The other headline figure in the release is the national average monthly bid amount for 2027: $296.05, calculated using June 2026 as the reference month. CMS explains its purpose in a single sentence — “The NAMBA is used to calculate the government subsidy for plans.” It governs how much of the program’s cost the federal government absorbs, which is also why it feeds the second half of the base premium formula.
The same release set two smaller figures aimed at plan sponsors rather than households: a de minimis amount of $2 for 2027, and a calendar-year prospective reinsurance amount of $63.21 per member per month for employer group waiver plans. Neither shows up on a consumer’s bill. Both are inputs to prices that will.
Real 2027 premiums arrive with the September landscape release
Nothing in the July announcement tells you what your own plan will charge. CMS was specific about when that arrives: “As in past years, CMS will release the 2027 MA and Part D landscape in mid-to-late September, once all offerings are finalized. In addition, CMS will release final average MA and Part D premiums, along with other key information, in September with the MA and Part D landscape.”
Until then, treat $41.33 as a yardstick rather than a forecast. When your 2027 plan premium appears, the gap between it and the benchmark is telling you something concrete: how your plan’s bid compares with the national average, whether rebates or a supplemental premium are in play, and whether a late enrollment penalty is riding along. Those are the adjustments CMS names, and they are the only reasons a plan-specific premium departs from the base.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
